COVID-19 adenovirus vaccine triggers antibodies against PF4 complexes to activate complement and platelets.
Anti-PF4 antibodies
Complement activation
Fcγ-receptor II
GPIIb/IIIa receptor
Platelets aggregation
Vaccine-induced thrombotic thrombocytopenia
Journal
Thrombosis research
ISSN: 1879-2472
Titre abrégé: Thromb Res
Pays: United States
ID NLM: 0326377
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
10
09
2021
revised:
14
10
2021
accepted:
28
10
2021
pubmed:
13
11
2021
medline:
21
12
2021
entrez:
12
11
2021
Statut:
ppublish
Résumé
Vaccine-induced thrombotic thrombocytopenia (VITT) is a rare coagulation disorder reported after administration of COVID-19 adenovirus-vectored vaccines. VITT is mediated by anti-platelet factor 4 (PF4) antibodies activating platelets through the Fcγ-receptor II (FcγRII), and it is associated with strong fibrin turnover. The complement system is involved in several other immunothrombotic entities, but its impact on VITT is not established. To assess antibodies in interaction with the activation of platelets and complement triggered by VITT. Antibodies against adenovirus type 2 hexon protein, ChAdOx1 adenoviral vector-specific IgG and PF4 were analyzed by enzyme immunoassays from VITT patients (n = 5). The EDTA plasma samples of the patients and controls were used to measure both terminal complement complexes (TCC) by ELISA and aggregation of healthy donor platelets. We studied the effects of human immunoglobulin (IVIG) and glycoprotein IIb/IIIa inhibitor (GPIIb/IIIa) on spontaneous and collagen-induced platelet aggregation supplemented with VITT plasma. None of the patients had experienced a COVID-19 infection. Antibody analyses confirmed the immunogenicity of the adenovirus-vectored ChAdOx1 vaccine. Moreover, VITT plasma had anti-PF4 antibodies and elevated TCC levels as a sign of complement activation. In isolated healthy donor platelets, VITT patient plasma caused marked, spontaneous aggregation of platelets, which was abolished by eptifibatide and high-dose therapeutic IVIG. Our findings suggest that VITT is triggered by antibodies against adenovirus vector and PF4-polyanion complexes which strongly co-activate complement and platelets. The spontaneous platelet aggregation was suppressed by IVIG or eptifibatide, indicating that besides FcγRII, also GPIIb/IIIa receptor exerts platelet procoagulant role in VITT.
Sections du résumé
BACKGROUND
Vaccine-induced thrombotic thrombocytopenia (VITT) is a rare coagulation disorder reported after administration of COVID-19 adenovirus-vectored vaccines. VITT is mediated by anti-platelet factor 4 (PF4) antibodies activating platelets through the Fcγ-receptor II (FcγRII), and it is associated with strong fibrin turnover. The complement system is involved in several other immunothrombotic entities, but its impact on VITT is not established.
OBJECTIVE
To assess antibodies in interaction with the activation of platelets and complement triggered by VITT.
METHODS
Antibodies against adenovirus type 2 hexon protein, ChAdOx1 adenoviral vector-specific IgG and PF4 were analyzed by enzyme immunoassays from VITT patients (n = 5). The EDTA plasma samples of the patients and controls were used to measure both terminal complement complexes (TCC) by ELISA and aggregation of healthy donor platelets. We studied the effects of human immunoglobulin (IVIG) and glycoprotein IIb/IIIa inhibitor (GPIIb/IIIa) on spontaneous and collagen-induced platelet aggregation supplemented with VITT plasma.
RESULTS
None of the patients had experienced a COVID-19 infection. Antibody analyses confirmed the immunogenicity of the adenovirus-vectored ChAdOx1 vaccine. Moreover, VITT plasma had anti-PF4 antibodies and elevated TCC levels as a sign of complement activation. In isolated healthy donor platelets, VITT patient plasma caused marked, spontaneous aggregation of platelets, which was abolished by eptifibatide and high-dose therapeutic IVIG.
CONCLUSIONS
Our findings suggest that VITT is triggered by antibodies against adenovirus vector and PF4-polyanion complexes which strongly co-activate complement and platelets. The spontaneous platelet aggregation was suppressed by IVIG or eptifibatide, indicating that besides FcγRII, also GPIIb/IIIa receptor exerts platelet procoagulant role in VITT.
Identifiants
pubmed: 34768097
pii: S0049-3848(21)00500-4
doi: 10.1016/j.thromres.2021.10.027
pmc: PMC8571998
pii:
doi:
Substances chimiques
Adenovirus Vaccines
0
COVID-19 Vaccines
0
Immunoglobulin G
0
Platelet Factor 4
37270-94-3
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
129-137Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Références
Semin Immunopathol. 2012 Jan;34(1):5-30
pubmed: 21818701
Front Immunol. 2014 Dec 18;5:649
pubmed: 25566260
Thromb J. 2021 Aug 23;19(1):59
pubmed: 34425822
Res Pract Thromb Haemost. 2021 Jul 02;5(5):e12551
pubmed: 34263103
Clin Appl Thromb Hemost. 2021 Jan-Dec;27:1076029620977702
pubmed: 33539214
Cell Mol Immunol. 2020 Apr;17(4):313-322
pubmed: 32152553
Methods Mol Biol. 2019;1901:191-196
pubmed: 30539578
N Engl J Med. 2021 Jun 10;384(23):2202-2211
pubmed: 33861525
Mol Immunol. 2010 Aug;47(13):2170-5
pubmed: 20621693
J Thromb Haemost. 2017 Nov;15(11):2099-2114
pubmed: 28846826
J Thromb Haemost. 2004 Jan;2(1):170-6
pubmed: 14717981
J Exp Med. 1979 Sep 19;150(3):633-45
pubmed: 479764
J Chromatogr. 1987 Jun 26;397:321-5
pubmed: 3654825
Blood. 2016 Jun 2;127(22):2701-10
pubmed: 27006390
J Infect Dis. 2021 Jul 15;224(2):218-228
pubmed: 33905505
Arterioscler Thromb Vasc Biol. 1997 Dec;17(12):3578-87
pubmed: 9437208
Platelets. 2013;24(5):383-91
pubmed: 22812520
Res Pract Thromb Haemost. 2021 Jun 01;5(5):e12529
pubmed: 34136745
Arterioscler Thromb Vasc Biol. 2001 Apr;21(4):628-35
pubmed: 11304482
N Engl J Med. 2021 Jun 3;384(22):2092-2101
pubmed: 33835769
Eur J Intern Med. 2013 Sep;24(6):496-502
pubmed: 23743117
Blood. 2021 Nov 25;138(21):2106-2116
pubmed: 34189574
J Biol Chem. 2007 Jan 5;282(1):710-20
pubmed: 17090548
J Thromb Haemost. 2006 Sep;4(9):2035-42
pubmed: 16961611
N Engl J Med. 2021 Jun 3;384(22):2124-2130
pubmed: 33835768
J Thromb Thrombolysis. 2021 Oct;52(3):689-691
pubmed: 34129181
mSphere. 2019 Sep 11;4(5):
pubmed: 31511367